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Abstract
Accumulated evidence suggests a relationship between specific allergic processes, such
as atopic eczema in children, and an aberrant fecal microbiota. However, little is known
about the complete microbiota profile of adult individuals suffering from asthma. We deter-
mined the fecal microbiota in 21 adult patients suffering allergic asthma (age 39.43 ± 10.98
years old) and compare it with the fecal microbiota of 22 healthy controls (age 39.29 ± 9.21
years old) using culture independent techniques. An Ion-Torrent 16S rRNA gene-based
amplification and sequencing protocol was used to determine the fecal microbiota profile of
the individuals. Sequence microbiota analysis showed that the microbial alpha-diversity
was not significantly different between healthy and allergic individuals and no clear cluster-
ing of the samples was obtained using an unsupervised principal component analysis. How-
ever, the analysis of specific bacterial groups allowed us to detect significantly lower levels
of bifidobacteria in patients with long-term asthma. Also, in allergic individuals the Bifido-
bacterium adolescentis species prevailed within the bifidobacterial population. The reduc-
tion in the levels on bifidobacteria in patients with long-term asthma suggests a new target
in allergy research and opens possibilities for the therapeutic modulation of the gut micro-
biota in this group of patients.
Introduction
In recent years, growing evidence supporting the “hygiene hypothesis“, which states that a lack
of early microbial stimulation results in aberrant immune responses to innocuous antigens
later in life, is rising [1,2]. It has also been suggested that modifications of the intestinal
PLOSONE | DOI:10.1371/journal.pone.0147809 February 3, 2016 1 / 11
OPEN ACCESS
Citation: Hevia A, Milani C, López P, Donado CD,
Cuervo A, González S, et al. (2016) Allergic Patients
with Long-Term Asthma Display Low Levels of
Bifidobacterium adolescentis. PLoS ONE 11(2):
e0147809. doi:10.1371/journal.pone.0147809
Editor: Christian U. Riedel, University of Ulm,
GERMANY
Received: September 12, 2015
Accepted: December 1, 2015
Published: February 3, 2016
Copyright: © 2016 Hevia et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement: The raw sequences
reported in this article have been deposited in the
NCBI Short Read Archive (SRA) (study accession
number: PRJNA276631). All other relevant data are
within the paper and its Supporting Information files.
Funding: This work was supported by AGL2010-
14952, http://www.idi.mineco.gob.es/.
Competing Interests: The authors have declared
that no competing interests exist.
microbiota composition that occur as a result of the westernized life-style has disrupted mecha-
nisms that are involved in the development of immunological tolerance [3]. In relation to this,
the scientific information about the relationship between allergy and gut microbiota dysbiosis
(an imbalance in the gut microbial ecology) is controversial nowadays. While some reports
highlight an aberrant microbiota associated with allergic manifestation, such as asthma, rhini-
tis, and eczema, others did not find any significant differences in the microbial profile, or spe-
cific microbial groups, in the gut microbiota of allergic individuals. This could be due to the
fact that different allergens can drive allergen-specific responses, to the lack of standardized
protocols to analyze the human microbiota, and because the studies were not performed in
well-defined population groups. For instance, some studies have indicated an association
between the gut microbiota composition and atopic disease, and there is solid evidence that
variations of particular intestinal microorganisms might be associated with this physiological
condition [4]. Also, a shift of the gut bacterial profiles has been associated with immune disor-
ders in infants and in adults [5–8], as well as in some food allergies, such as milk-hypersensitiv-
ity [9,10]. However, despite some positive results, strategies to ameliorate the clinical
manifestations of allergy through the modulation of the intestinal microbiota using probiotic
microorganisms yielded limited results [11,12].
In this work we performed a cross-sectional study in which we characterized the microbiota
of a representative group of adult patients suffering allergic asthma and compared it with a
group of healthy controls. We used a 16S rRNA gene-based analysis protocol for this purpose.
Significant differences in the bifidobacterial population of asthmatic patients were highlighted.
Materials and Methods
Ethical Statement
Ethics approval for this study (reference code AGL2010-14952; grant title “Towards a better
understanding of gut microbiota functionality in some immune disorders”) was obtained from
the Bioethics Committee of CSIC (Consejo Superior de Investigaciones Científicas) and from
the Regional Ethics Committee for Clinical Research (Servicio de Salud del Principado de Astu-
rias) in compliance with the Declaration of Helsinki and we have obtained permission from
participants to publish potentially identifying case details. All determinations were performed
with fully informed written consent from all participants involved in the study. The study did
not interfere with patients’ normal care.
Study subjects
The study sample comprised 21 patients with allergic asthma (AL codes; 9 male and 12
female; age 39.43 ± 10.98, and 22 healthy controls (HC codes, 7 male and 15 female, age
39.29 ± 9.21). Patient recruitment was carried out in the allergology consultation of the Cen-
tral University Hospital of Asturias. Information on clinical manifestations was obtained by
reviewing clinical records and by personal interviews. Asthma diagnosis was stablished based
on the criteria of the Global Initiative for Asthma—GINA [13]. Inclusion criteria also
included confirmed diagnosis of asthma (with or without rhinitis) due to perennial allergens.
The diagnosis was stablished when patients had a positive skin test and serum-specific IgE
levels greater or equal to 3.5 kU/L, with clinically related symptoms. Common relevant anti-
gens were usually house dust mite (HDM), grasses, dog epithelia and a work place allergen
(green coffee). All patients were sensitized to HDM and had a positive Skin Prick Test (SPT)
result to at least one of the tested allergens.
Serum total IgE, serum-specific IgE testing and SPT were determined at the same time of
fecal sampling (Table 1). All patients were diagnosed as persistent asthma with regular control
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treatment. Most of the patients required daily treatment with inhaled glucocorticosteroid (low
or medium dose) alone or with Laba (long-acting beta agonist) (step of treatment 2, 3 or 4 of
GINA). Five patients [AL7, AL9, AL11, AL15 and AL16] only required inhaled treatment in a
discontinuous way (step 1 or 2 of GINA). All patients excluding AL3, AL7, AL18 and AL19
were suffering perennial rhinitis. AL3, AL7, AL18 and AL19 were suffering intermittent rhinitis
or no rhinitis.
The exclusion criteria considered for this study included subjects diagnosed as having auto-
immune diseases, inflammatory bowel disease, or other diseases known to affect intestinal
function, as well as subjects who received immunosuppressive therapy and/or allergen specific
immunotherapy in the last 5 years (excluding patient AL1 who received an incomplete treat-
ment of immunotherapy [6 months only] 20 months before the fecal sample collection).
Patients with oral glucocorticoid or antibiotic treatments during the 6 months prior to the sam-
ple collection date were also excluded from the study.
Skin Prick Tests
Thirteen allergens representing the most relevant inhalant allergens in allergic rhinitis and
asthma in Spain according to previous studies [14] (Dermatophagoides pteronysinus, Lepidogli-
phus destructor, Betula berrucosa, Cypresus sempervirens, Platanus hispánica, Lolium perenne
and Plantago lanceolata, dog and cat dander, Alternaria alternata, Cladosporium herbarum,
Table 1. Relevant demographic and clinical features of AL patients.
Sample Age
(years)
Sex IgE Titer
(IU/ml)
SPT Relevant causal
agent*
Speciﬁc IgE
(KU/l)
Rhinitis duration
(years)
Asthma duration
(years)
AL1 40 F 160 HDM D. pteronysinus 17.5 40 40
AL2 27 F 133 HDM D. pteronysinus 32 12 1.5
AL3 24 F 2799 HDM, dog epithelia Dog epitehlia >100 - 2.0
AL4 55 M 388 HDM D. pteronysinus 16 12 19
AL5 36 M 187 HDM, grasses Lepidoglyphus 28 3 3
AL6 46 F 715 HDM, grasses,
green cafe
Green coffe 45 30 20
AL7 38 M 104 HDM Lepidoglyphus 10 - 38
AL8 49 F 173 HDM D. pteronysinus 20 10 4
AL9 51 F 389 HDM Cat epithelia 42 33 3.5
AL10 37 M 235 HDM D. pteronysinus 52 32 14
AL11 32 F 608 HDM, grasses D. pteronysinus 75 27 15
AL12 54 F 87 HDM D. pteronysinus 15 52 5
AL13 38 F 62 HDM D. pteronysinus 12 23 11
AL14 57 M 87 HDM D. pteronysinus 12 52 32
AL15 27 M 158 HDM D. pteronysinus 37 7 23
AL16 37 F 76 HDM D. pteronysinus 10 12 4
AL17 50 F 119 HDM D. pteronysinus 34 45 11
AL18 22 M 300 HDM D. pteronysinus 58 - 3
AL19 22 F 89 HDM D. pteronysinus 15 - 7
AL20 42 M 110 HDM D. pteronysinus 7 37 34
AL21 44 M 484 HDM D. pteronysinus 63 30 38
SPT, Skin Prick Test.
HDM, House Dust Mites.
* More relevant agent in perennial symptoms.
doi:10.1371/journal.pone.0147809.t001
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Peniccillium notatum and Aspergillus fumigatus) were obtained from Leti S.A. (Spain) or Alk
Bello (Spain). For skin prick tests, all allergens were standardized using biological units [15].
Green coffee was tested 1/10 weight/volume in saline serum. A SPT was considered positive
when the patient developed a wheal larger than a histamine wheal or larger than 3 mm.
Total IgE and specific IgE determination
InmunoCAP Total IgE and ImmunoCAP Specific IgE (Thermo Fisher) were used to determine
the total IgE and specific IgE, respectively. Methods were carried out according to the manufac-
turer’s instructions.
Fecal sample collection and DNA extraction
Fresh fecal material (between 10 and 50 grams per person) was collected in sterile containers
and immediately manipulated and homogenized within a maximum of 3 hours from defeca-
tion. During the time between defecation to homogenization, samples were kept at 4°C. Thirty
ml of RNAlater solution (Applied Biosystems, Foster City, CA) were added to 10 grams of sam-
ple and the mixture was homogenized in sterile bags, using a stomacher apparatus (IUL Instru-
ments, Barcelona, Spain) (three cycles at high speed, one minute per cycle). Homogenized
samples were then stored at -80°C until use. For DNA extraction, samples were thawed and the
QIAamp DNA Stool Mini kit was used (Qiagen Ltd., Strasse, Germany), as previously
described [16].
16S rRNA gene amplification and sequencing of 16S rRNA gene-based
amplicons
Primer selection, amplicon generation and purification, amplicon library construction and
sequencing were performed essentially as described by Hevia et al. [17]. Briefly, the primer pair
Probio_Uni / Probio_Rev [16] was used to generate amplicon pools of approximately 200 bp
length. The integrity of the PCR amplicons was analyzed by electrophoresis prior to their puri-
fication using the Wizard SV Gen PCR Clean-Up System (Promega, Madison, WI), and the
Agencourt AMPure XP DNA purification beads (Beckman Coulter Genomics GmbH, Bern-
ried, Germany). Libraries for each run were diluted to 3E9 DNA molecules prior to clonal
amplification. Emulsion PCR was carried out using the Ion OneTouch™ 200 Template Kit v2
DL (Life Technologies, Guilford, CA) and sequencing of the amplicon libraries was carried out
on 316 chips using the Ion Torrent PGM system and employing the Ion Sequencing 200 kit
(Life Technologies). After sequencing, individual sequence reads were filtered by the PGM soft-
ware to remove low quality and polyclonal sequences. Sequences matching the PGM 3’ adaptor
were also automatically trimmed. All PGM quality-approved, trimmed and filtered data were
exported as SFF files.
Sequence-based microbiota analysis
The SFF files were processed using QIIME [18]. Quality control retained sequences with an
average length of 180 bp (S1 Table), mean sequence quality score>25, with truncation of a
sequence at the first base if a low quality rolling 10 bp window was found. Presence of homo-
polymers>7 bp, and sequences with mismatched primers were omitted. In order to calculate
alpha and beta diversity indices, 16S rRNA Operational Taxonomic Units (OTUs) were
defined at 97% sequence homology using uclust [19]. Chimeric sequences were removed
using ChimeraSlayer [20]. All reads were classified to the lowest possible taxonomic rank using
QIIME and a reference dataset from the Ribosomal Database Project [21].
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Nucleotide sequence accession number
The raw sequences reported in this article have been deposited in the NCBI Short Read Archive
(SRA) (study accession number: PRJNA276631).
Statistical analyses
Statistical analysis was performed using IBM-SPSS version 19.0 (IBM SPSS, Inc., Chicago, IL).
Individuals were ordered according to their sequence data composition by Principal Compo-
nent Analysis using the taxonomic data at the phylum and family level. Patterns were extracted
using all the variation from the taxonomic data using an indirect method as model, and allergy
as metadata. Significant differences between healthy controls and asthmatic patients were only
considered below a p-value of 0.05. The p-values at the phylum, family and genus level are
included in S2 Table. Multivariate linear regression was performed in order to identify the clin-
ical and demographical features associated with the levels of B. adolescentis in asthmatic indi-
viduals. The statistical parameters employed were β (standardized regression coefficient) and
R2 (coefficient of multiple determinations). The conventional probability value for significance
(0.05) was used in the interpretation of results.
Results
To shed some light on the potential relationship between the human microbiota and allergy,
we analyzed the fecal microbiota of 21 subjects suffering from allergic asthma. We followed
strict exclusion criteria trying to minimize the influence of environmental and genetic factors
on our analysis. We considered a homogeneous group, with a very specific pathology: con-
firmed allergic asthma. Clinical history of the patients and the evidence of an IgE mediated dis-
ease are the main criteria in our analysis, in order to associate the microbiota profile in a highly
selected allergic group. Fig 1 shows the microbiota composition at phylum, family and genus
level that was obtained for healthy individuals and asthmatic persons. Rarefaction curves
obtained by plotting the Shannon and Chao1 indexes against the number of sequences (S1 Fig)
showed that a large part of the diversity of the samples was detected. We did not obtain signifi-
cant alpha-diversity indexes (Chao1, PDWhole Tree, Observed Species, Shannon and Simpson
indexes) between asthmatic and healthy individuals (data not shown). Furthermore, individu-
als were ordered according to their sequence data composition by Unsupervised Principal
Component Analysis (PCA) using the taxonomic data at the phylum, family and genus level.
No clear clustering of the samples was obtained at the three different levels analyzed (Fig 2
shows the plot obtained using genus level), suggesting that the characteristics of the microbiota
are similar considering the sample sets of sequences in both population groups.
In our study, we organized relevant data of the patients (age, sex, total and specific IgE titers,
causal agent, rhinitis, disease duration) in a metadata file for all the microbiota profiles. Both
metadata/microbiota profiles were loaded in STAMP v2.0.3 and a PCA analysis performed
using the variability of the 16S rRNA gene profiling at different taxonomic levels. Sample clas-
sification according to the metadata revealed no specific clustering of the samples or correla-
tion with different clinical features and analytical results. Furthermore, our results do not
stablish a link between microbial groups and asthma when the fecal microbiota was analyzed
in its entirety, and statistically significant differences between healthy controls and asthmatic
patients were only detected for Faecalibacterium and Bifidobacterium at the genus level (both
genera were more abundant in allergic asthma patients; S2 Table). However, when we exam-
ined the possible relationship between the bacterial groups present in the fecal samples and the
time suffering from asthma, we found that low levels of bifidobacteria correlate with long ail-
ment periods of asthma (Fig 3). Although the amplicons of the 16S sequences could be
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Fig 1. Aggregate microbiota composition in faecal samples from healthy controls and allergic asthma patients at phylum level (panel a), family
level (panel b) and genus level (panel c). In panels b and c only taxonomic groups above 0.5% are shown.
doi:10.1371/journal.pone.0147809.g001
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relatively short to perform a totally reliable population structure analysis at species level, it is
noteworthy that the relative abundance of sequences assigned to Bifidobacterium adolescentis
was significantly higher in allergic asthma samples. Remarkably, in asthmatic individuals the B.
adolescentis species prevailed, but in healthy controls a group of other species (Bifidobacterium
longum, Bifidobacterium breve and Bifidobacterium bifidum) constituted the majority of the
bifidobacterial population. Furthermore, if we subcategorize the allergic asthma patients con-
sidering the median for asthma ailment (11 years), the means of the B. adolescentis population
in the two groups (long-term asthma and short-term asthma groups;> or< 11 years suffering
from asthma) are significantly different (ANOVA test, p<0.002). Remarkably, our observa-
tions were significantly relevant for allergic asthma but not for duration of allergic rhinitis. Fur-
thermore, using a Spearman Ranked Scores analysis, the levels of Bifidobacterium and of B.
adolescentis were negatively correlated with the asthma duration (correlation coefficient
-0,84074, p-value: 3,4588E-06 for Bifidobacterium; correlation coefficient -0,84682, p-value:
2,494E-06 for B. adolescentis). On the other hand, a multivariate linear analysis showed that
the time suffering the disease and the IgE titer were identified as B. adolescentis predictor
Fig 2. Principal Component Analysis using the 16S rRNAmetagenomic profiles and the genus level.
Presence/absence of asthma was further included as metadata. (Green squares: healthy controls; blue
circles: asthmatic patients).
doi:10.1371/journal.pone.0147809.g002
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variables. We found that there is a negative association of B. adolescentis with the time suffering
the disease (β = -0.457), and a positive association with total IgE levels (β = 0.444), p model
<0.001. Other clinical or demographical variables such as sex, age, most relevant causal aller-
gen, specific IgE or time of rhinitis disease did not show any association.
Fig 3. Correlation between the time of asthma ailment and the abundance of bifidobacteria (A) and B.
adolescentis (B) in allergic asthma patients.
doi:10.1371/journal.pone.0147809.g003
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Discussion
The microbiota plays an integral role in the homeostasis of multiple interconnected host meta-
bolic and immune networks. There is solid experimental evidence that gut microbiota regulates
our inflammatory immune response [22]. Disturbed gut colonization patterns have been asso-
ciated with allergic disease but whether microbial variation is the cause or effect of these dis-
eases is still under investigation. Whereas some authors have established a link between
specific microbial profiles and allergy, other authors suggest that this should not be considered
in broad terms and that it depends on the clinical manifestation of the allergic reaction and of
the specific antigens triggering the immune response [9, 23,24].
Previous studies in infant/children populations have shown that lower levels of bifidobac-
teria are found in feces of allergic subjects compared with non-allergic individuals. However,
the present work, performed in a well-defined population of allergic asthma adults, shows that
the relative abundance of bifidobacteria is higher in the asthma group, suggesting an influence
of this particular pathology on shaping bifidobacterial ecology in the gut. In relation to this,
infants of atopic mothers were the only ones to be colonized with B. adolescentis and infants
from allergic mothers had lower counts of bifidobacteria in feces than infants from non-allergic
mothers [25]. Furthermore, Stsepetova et al. [26] indicated a less diverse composition of intesti-
nal microbiota and prevalence of B. adolescentis in allergic childrens, and He et al. [27] found
that B. adolescentis is found more often in the fecal microbiota of allergic childrens than in
non-allergic ones. Thus, from previous works it seems that there is an association between B.
adolescentis and allergy. The novelty of our findings is that, to our knowledge, this is the first
time that bifidobacteria in general, and B. adolescentis in particular, has been associated with
the ailment of allergic asthma. Remarkably, higher levels of Faecalibacterium were detected in
the asthmatic patients; this finding could be related to the regular treatment with anti-inflam-
matory drugs of most of the patients, since the presence of Faecalibacterium is normally
decreased during inflammatory process [28].
In summary, our data suggest that there is not a significant difference between the fecal
microbiota profile of allergic subjects suffering from asthma and healthy individuals, neither a
different microbial diversity. However, lower bifidobacterial levels are present in asthmatic
individuals with long-term asthma, compared with those whose asthma was diagnosed more
recently. Our findings suggest that the differences in the bifidobacterial populations in control
vs asthma groups, as well as in short-term vs long-term asthma groups, could be explored fur-
ther in order to develop novel treatments based on gut microbiota modulation. The results
obtained also contribute to generate knowledge on the potential role of bifidobacteria in the
physiology of allergy, and support the potential use of strains of these genera as probiotics to
modulate allergy symptoms.
Supporting Information
S1 Fig. Rarefaction curves generated for 16S rRNA gene sequences obtained from faecal
samples of control subjects (HC samples) and allergic asthma patients (AL samples). Panel
a represents the rarefaction curves using the Shannon index. Panel b displays rarefaction curves
using the Chao1 index.
(DOCX)
S1 Table. Sequence data features.
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(AL) at the phylum, family and genus levels.
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